Investigational oral regimen for hepatitis C shows promise in NIH trial. Side effects minimized with combination therapy in hard-to-treat patients In a study of an all-oral drug regimen, a majority of volunteers with liver damage due to hepatitis C virus (HCV) infection were cured following a six-month course of therapy that combined an experimental drug, sofosbuvir, with the licensed antiviral drug ribavirin.
The results showed that the regimen was highly effective in clearing the virus and well tolerated in a group of patients who historically have had unfavorable prognoses. Scientists from the National Institute of Allergy and Infectious Diseases (NIAID) and the NIH Clinical Center, parts of the National Institutes of Health, led the Phase II trial. The findings appear in the Aug. 28 issue of the Journal of the American Medical Association (JAMA). Viral Hepatitis Monthly: April 2013. In the month of April, Hep B United Philadelphia will be focusing on vaccine clinics and outreach.
There are three hepatitis B vaccines taking place in April, covering the areas of South, North, and Northeast Philadelphia. You can also find us around town quite a bit! We will be at the Wellness Across the Lifespan Community Health Fair located at 6219 Lancaster Avenue on Saturday, April 20 from noon to 5pm providing outreach and education. Also on April 20, we will be joining HepCAP at the Science Festival on the Parkway - come meet O'Liver, our healthy liver mascot! On April 24, we will be at the 7th Annual Faith and Spiritual Affairs Conference put on by Philadelphia’s Department of Behavior Health and Intellectual disAbility Services. HepCAP: March Mtn Highlights and May Save the Dates.